Health & biology · August 2026

Pan-RAS inhibitor for pancreatic cancer

A pill that blocks mutant RAS doubles survival in pancreatic cancer.

The FDA approved Revolution Medicines' daraxonrasib for metastatic pancreatic cancer. In a 500-patient trial, median survival was 13.2 months versus 6.7 on chemotherapy, drugging a cancer driver long called undruggable.

See it in the living tree Wikipedia Source

Arcs above join it to what it stood on, arcs below to what it led to. The bar places this stretch on the tree's whole timeline.

What it built on 2

Human Genome Project 2003
Monoclonal antibodies 1974

Related measurements

The dashed line marks when it first worked.

Life expectancy at birth Latest: 73.2 years (2023) Source: Our World in Data